By Stephen Nakrosis
Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five potential disease targets.
Under the terms of the deal, Lilly is granted world-wide exclusive license to utilize STAC-BBB for one initial target, and has the right to add up to four additional targets after paying additional licensed target fees.
The deal will see Sangamo receive $18 million as an upfront license fee. Under the terms of the agreement, Sangamo is eligible to receive up to $1.4 billion in additional license fees, milestone payments and tiered royalties, the companies said.
Sangamo is responsible for completing a technology transfer related to STAC-BBB, while Lilly is responsible for all research, preclinical and clinical development, regulatory interactions, manufacturing, and global commercialization of any resulting gene therapy products, the companies said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 03, 2025 16:30 ET (20:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。